Martin Vogel, Therapeutic Area Lead for Oncology, Janssen EMEA, discusses the potential of bispecific monoclonal antibodies like amivantamab to address unmet needs in advanced non-small cell lung cancer treatment.
Data announced at the European Lung Cancer Congress (ELCC) earlier last month revealed the long-term efficacy and safety of RYBREVANT® (amivantamab) in patients with post-platinum EGFR Ex20ins-mutated advanced non-small cell lung cancer (NSCLC). Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
Martin Vogel, Janssen’s Therapeutic Area Lead Oncology for the Europe, Middle-East and Africa (EMEA) region shared with EPR what makes the BsMAb promising for treating this indication.
The data is important because there is “high unmet need for novel and targeted therapies for this patient population” Vogel stated. These patients experience poorer prognosis and shorter survival rates compared to lung cancer driven by more common EGFR mutations.
According to Research and Markets8, the market for bispecific antibodies for cancer is forecasted to grow by $400 million during 2022-2027, due to the increasing prevalence of cancer worldwide. New bispecific antibody generation platforms were identified as one of the major drivers of the market in the next few years.
Why are bispecific monoclonal antibody drugs such as amivantamab promising for this indication?
Amivantamab is the first and only approved treatment in the EU for adults with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations, after failure of platinum-based therapy.1″
Amivantamab is the first and only approved treatment in the EU for adults with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations, after failure of platinum-based therapy.1 Existing oral, targeted EGFR tyrosine kinase inhibitor (TKI) therapies provide an effective treatment option for more common NSCLC EGFR mutations but have generally not been shown to be effective in this patient population.2, 3
The treatment was engineered to simultaneously bind with high affinity and inhibit both EGFR and MET, which are two important pathways in NSCLC development and progression.4 Amivantamab targets the extracellular portion of the EGFR and MET receptors. It potentially bypasses the inherent resistance these mutations had exhibited to previously approved TKIs. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity.4
By targeting both MET and EGFR receptors, amivantamab can counteract the resistance that develops. This is due to overlapping signalling pathways of both receptors and the compensatory changes that occur in one pathway following inhibition of the other.4 BsMAb amivantamab was designed to enhance adherence of tumour cells to macrophages and natural killer cells, to improve immune-cell mediated killing of cancer cells.4, 5
Why was the data presented at ELCC 2023 on the bispecific monoclonal antibody significant?
These clinically meaningful results from Cohort D of the CHRYSALIS study confirmed the longer-term safety and efficacy data for amivantamab in patients with an EGFR Exon20 insertion mutation and metastatic NSCLC who have progressed on chemotherapy. These patients face a poorer prognosis and shorter survival rates compared with lung cancer driven by more common EGFR mutations.1
This is significant as the standard of care for common EGFR mutations, such as EGFR TKIs, are generally ineffective against EGFR exon 20 insertion mutations. They are not US Food and Drug Administration (FDA)-approved for these patients due to the lack of benefit.3,4 There is a high unmet need for novel and targeted therapies for this patient population.
What are the current trends in antibody therapeutics?
The next wave of lung cancer innovations includes addressing challenging targets with novel chemistry and modalities and pursuing novel targets for solid tumours”
The next wave of lung cancer innovations includes addressing challenging targets with novel chemistry and modalities and pursuing novel targets for solid tumours. In addition, immuno-oncology, or identifying how to leverage a patient’s immune system, is a key capability and part of our focus on patients with advanced cancer and on cancer interception.6
Precision medicine also offers the opportunity for more effective treatments targeted against the biological mechanisms causing disease, rather than the usual trial and error approach.7 Such an approach has the potential to optimise treatment outcomes for patients and improve quality of care.
References
1. Garrido P et al. Long-term efficacy, safety and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC. ELCC 2023. Oral Presentation JGN-75414.
2. Nan X, Xie C, Yu X, Liu J. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget. 2017; 8(43): 75712–26.
3. Hou J, Li H, Ma S, et al. Z. EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: Current status and Perspectives. Biomark. Res. 2022; 10(1).
4. Byoung Chul C et al. Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications. Clinical Lung Cancer. 2022; 24(2): 89 – 97.
5. Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an FC enhanced EGFR/CMET bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Mol. Cancer Ther. 2020; 19(10): 2044–56.
6. Finn OJ, et al. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012; 23(8): 6 – 9.
7. Personalized medicine at FDA. [Internet] Personalized Medicine Coalition. 2021. [cited 2023Apr. Available from: https://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/Personalized_Medicine_at_FDA_The_Scope_Significance_of_Progress_in_2021.pdf.
8. Global Bispecific Antibodies for Cancer Market 2023-2027. [Internet] Research and Markets. 2023. [cited 2023Apr]. Available from: https://www.researchandmarkets.com/reports/5557994/global-bispecific-antibodies-for-cancer-market?utm_source=GNOM&utm_medium=PressRelease&utm_code=9st6hf&utm_campaign=1830556+-+Global+Bispecific+Antibodies+for+Cancer+Market+Report+2023-2027%3a+Increasing+Prevalence+of+Cancer%2c+Advantages+of+Bispecific+Antibodies+Over+Monoclonal+Antibodies%2c+and+Strong+Pipeline+Drives+Growth&utm_exec=como322prd.
About the author
Martin Vogel is Therapeutic Area Lead Oncology for Janssen Europe, Middle-East and Africa (EMEA). Martin drives the overall oncology strategy for the region, supporting activities around unmet patient needs and access into Janssen’s global development plan.
Catherine Eckford is Editorial Assistant at European Pharmaceutical Review.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.